Allogene Therapeutics Advances in CAR T Cell Therapy

Allogene Therapeutics ( (ALLO) ) has released its Q2 earnings. Here is a breakdown of the information Allogene Therapeutics presented to its investors.

Allogene Therapeutics is a clinical-stage biotechnology company based in South San Francisco, specializing in the development of allogeneic CAR T cell therapies for cancer and autoimmune diseases. The company is known for its innovative ‘off-the-shelf’ cell therapy products aimed at providing scalable and accessible treatment options.

In its latest earnings report for the second quarter of 2025, Allogene Therapeutics highlighted significant advancements in its clinical trials and financial performance. The company is progressing with its pivotal Phase 2 ALPHA3 trial for large B-cell lymphoma and has initiated the Phase 1 RESOLUTION trial in autoimmune diseases. Additionally, Allogene has aligned with the FDA on a pivotal trial design for its ALLO-316 product in renal cell carcinoma.

Key financial metrics from the report include research and development expenses of $40.2 million and general and administrative expenses of $14.3 million for the quarter. The company reported a net loss of $50.9 million, or $0.23 per share, and ended the quarter with $302.6 million in cash, cash equivalents, and investments. Allogene’s cash runway is projected to extend into the second half of 2027.

Strategically, Allogene is focusing on expanding its clinical trial footprint internationally and exploring potential partnerships to advance its programs. The company’s use of CRISPR-based technology and its Dagger® platform are central to its approach in developing effective and durable cell therapies.

Looking ahead, Allogene Therapeutics remains committed to advancing its pipeline of cell therapy products, with upcoming milestones including a futility analysis for the ALPHA3 trial and proof-of-concept data for the RESOLUTION trial expected in the first half of 2026. The company aims to continue its disciplined execution strategy to create value and deliver innovative therapies to patients.